Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Mechanism of action

2 evidence topics · 2 sources

Local inhibition of mTOR signaling: formulation design

“to deliver rapamycin directly to pathogenic skin tissue to achieve local, on-target inhibition of mTOR signaling while minimizing systemic exposure.” (opens the source at this quote in a new tab)

Targeted delivery

“QTORIN provides targeted rapamycin delivery to the main area of concern, usually within the deep layers of the epidermis or dermis.” (opens the source at this quote in a new tab)